Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fludarabine + anti-thymocyte globulin + busulfan
- Development stage
- Phase 2
- Lead developer
- Bayer
- Modality
- Small Molecules, Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Fludarabine + anti-thymocyte globulin + busulfan (Flu/ATG/Bu or FBx-ATG) is a reduced-intensity or reduced-toxicity conditioning regimen used prior to allogeneic hematopoietic stem cell transplantation (HSCT). The regimen combines three distinct agents to prepare the recipient's bone marrow and immune system for donor engraftment: fludarabine, a purine nucleoside analog that acts as a lymphodepleting antimetabolite; anti-thymocyte globulin (ATG), a polyclonal antibody biologic that depletes T cells to prevent graft rejection and graft-versus-host disease (GvHD); and busulfan, a bifunctional alkylating agent that cross-links DNA to achieve myeloablation. This combination is widely utilized in the transplantation process for both malignant hematologic conditions (such as acute myeloid leukemia, myelodysplastic syndromes, and lymphomas) and non-malignant disorders (including severe aplastic anemia, sickle cell disease, and Fanconi anemia).
- Other names
- FBx-ATGFlu/ATG/BuFlu/Bu/ATGfludarabine + antithymocyte globulin + busulfanfludarabine, anti-thymocyte globulin, and busulfanfludarabine, antithymocyte globulin, and busulfan
02
Targets
DNAPOLA1 (DNA polymerase alpha)RNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on fludarabine + anti-thymocyte globulin + busulfan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fludarabine + anti-thymocyte globulin + busulfan.